HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026
Pancreatic enzyme replacement therapy for prevention of postpancreatectomy hepatic steatosis after pancreatoduodenectomy: a post hoc analysis of a randomized placebo-controlled trial.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Moonhwan, Yoon Yoo-Seok, Jang Jin-Young, Kwon Wooil, Kim Hongbeom, Yoon Dong-Sup, Park Joon S, Lee Seung E, Lee Jun S, Han Ho-Seong
Аннотация
BACKGROUND: Postpancreatectomy hepatic steatosis (PHS) is a long-term complication after pancreaticoduodenectomy (PD). We investigated the association between PERT and the development of PHS.
METHODS: Among patients randomized to PERT or placebo after PD in a previous prospective study (NCT02127021), 94 patients with preoperative and 1-year postoperative unenhanced computed tomography (CT) were included. PHS was defined as liver attenuation of <40 Hounsfield units (HU) or liver-to-spleen attenuation difference of ≥10 HU on non-contrast CT.
RESULTS: The PERT group contained 42 patients and the placebo group contained 52 patients. The incidence of PHS at 1 year was significantly lower in the PERT group compared with the placebo group (9.5% vs. 23.1%, p < 0.001). Independent risk factors in the multivariable analysis were placebo intake (OR 2.376, p < 0.001) and body weight loss of >5% at 3 months postoperatively (OR 1.602, p = 0.046). Subgroup analysis confirmed that PERT consistently reduced the incidence of PHS in patient with body weight loss of >5% after 3 months of medication administration.
CONCLUSIONS: PERT was associated with a significantly lower incidence of PHS after PD than placebo, with sustained benefits in patients with significant postoperative body weight loss.
METHODS: Among patients randomized to PERT or placebo after PD in a previous prospective study (NCT02127021), 94 patients with preoperative and 1-year postoperative unenhanced computed tomography (CT) were included. PHS was defined as liver attenuation of <40 Hounsfield units (HU) or liver-to-spleen attenuation difference of ≥10 HU on non-contrast CT.
RESULTS: The PERT group contained 42 patients and the placebo group contained 52 patients. The incidence of PHS at 1 year was significantly lower in the PERT group compared with the placebo group (9.5% vs. 23.1%, p < 0.001). Independent risk factors in the multivariable analysis were placebo intake (OR 2.376, p < 0.001) and body weight loss of >5% at 3 months postoperatively (OR 1.602, p = 0.046). Subgroup analysis confirmed that PERT consistently reduced the incidence of PHS in patient with body weight loss of >5% after 3 months of medication administration.
CONCLUSIONS: PERT was associated with a significantly lower incidence of PHS after PD than placebo, with sustained benefits in patients with significant postoperative body weight loss.